Gudny Ella Thorlacius1, Marie Wahren-Herlenius1, Lars Rönnblom2. 1. Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm. 2. Department of Medical Sciences, Science for Life Laboratory, Rheumatology, Uppsala University, 751 85 Uppsala, Sweden.
Abstract
PURPOSE OF REVIEW: Systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS) share several clinical and laboratory features, including an overexpression of type I interferon (IFN) regulated genes. The genetic background to this IFN signature and the role of the type I IFN system in the disease process have been partly clarified. Here, we summarize the latest information concerning the type I IFN system in both diseases. RECENT FINDINGS: A number of gene variants in the type I IFN signalling pathways associate with an increased risk for both SLE and pSS in several ethnicities. The function of some risk gene variants has been elucidated, as well as the importance of epigenetic changes in type I IFN regulated genes. MicroRNA-451 and miR-302d have been shown to target IFN regulatory factor 8 and 9, suggesting that noncoding RNAs can control the IFN system. A prominent type I IFN activation is related to several disease manifestations, and in SLE to a more severe disease phenotype. Phase II studies in SLE suggest beneficial effects of blocking the type I IFN receptor. SUMMARY: The activated type I IFN system in SLE and pSS has a strong genetic component, is important in the disease etiopathogenesis and can be targeted.
PURPOSE OF REVIEW: Systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS) share several clinical and laboratory features, including an overexpression of type I interferon (IFN) regulated genes. The genetic background to this IFN signature and the role of the type I IFN system in the disease process have been partly clarified. Here, we summarize the latest information concerning the type I IFN system in both diseases. RECENT FINDINGS: A number of gene variants in the type I IFN signalling pathways associate with an increased risk for both SLE and pSS in several ethnicities. The function of some risk gene variants has been elucidated, as well as the importance of epigenetic changes in type I IFN regulated genes. MicroRNA-451 and miR-302d have been shown to target IFN regulatory factor 8 and 9, suggesting that noncoding RNAs can control the IFN system. A prominent type I IFN activation is related to several disease manifestations, and in SLE to a more severe disease phenotype. Phase II studies in SLE suggest beneficial effects of blocking the type I IFN receptor. SUMMARY: The activated type I IFN system in SLE and pSS has a strong genetic component, is important in the disease etiopathogenesis and can be targeted.
Authors: Sarthak Gupta; Shuichiro Nakabo; Luz P Blanco; Liam J O'Neil; Gustaf Wigerblad; Rishi R Goel; Pragnesh Mistry; Kan Jiang; Carmelo Carmona-Rivera; Diana W Chan; Xinghao Wang; Hege L Pedersen; Manasi Gadkari; Katherine N Howe; Faiza Naz; Stefania Dell'Orso; Sarfaraz A Hasni; Caeden Dempsey; Ashley Buscetta; Pamela A Frischmeyer-Guerrerio; Paul Kruszka; Maximilian Muenke; Luis M Franco; Hong-Wei Sun; Mariana J Kaplan Journal: Proc Natl Acad Sci U S A Date: 2020-06-29 Impact factor: 11.205
Authors: Bethany D Harris; Srilalitha Kuruganti; Ashlesha Deshpande; Paul A Goepfert; W Winn Chatham; Mark R Walter Journal: Lupus Date: 2020-07-01 Impact factor: 2.911
Authors: Yury Chaly; Jennifer Y Barr; David A Sullivan; Helen E Thomas; Thomas C Brodnicki; Scott M Lieberman Journal: Int J Mol Sci Date: 2018-10-20 Impact factor: 5.923
Authors: Marta E Alarcón-Riquelme; Pedro Carmona-Sáez; Jordi Martorell-Marugán; Raúl López-Domínguez; Adrián García-Moreno; Daniel Toro-Domínguez; Juan Antonio Villatoro-García; Guillermo Barturen; Adoración Martín-Gómez; Kevin Troule; Gonzalo Gómez-López; Fátima Al-Shahrour; Víctor González-Rumayor; María Peña-Chilet; Joaquín Dopazo; Julio Sáez-Rodríguez Journal: BMC Bioinformatics Date: 2021-06-24 Impact factor: 3.169